What bDMARDs are available to inhibit IL 17

What bDMARDs are available to inhibit IL 17 in the rheumatic diseases?

Secukinumab (Cosentyx) is a human IgG1κ monoclonal antibody which blocks IL-17A. It is FDA-approved to treat psoriasis, PsA, and AS. Not effective for RA.

  • • Available formulations: 150 mg/mL solution in a single-use Sensoready pen or prefilled syringe that is self-administered. There is also a 150-mg lyophilized powder form for reconstitution and administration in office by a healthcare professional (Medicare part B insurance coverage eligible).
  • • Adult PsA and AS dosage: 150 mg SC weekly × 4 (loading dose), then 150 mg SC every 4 weeks. Can be combined with a csDMARD (e.g., MTX).
  • • Monitoring: routine monitoring for other csDMARDs (e.g., MTX).
  • • Adverse reactions: injection site reactions, nasopharyngitis are most common. IL-17 is important for resistance to fungal infections. Opportunistic infections especially Candida have been reported. Development and/or exacerbation of Crohn’s disease have been reported.
  • • Precautions: do not use in patients with active infection. Do not combine with other bDMARDs.

Ixekizumab (Taltz) is a humanized monoclonal antibody to IL-17A, which is FDA-approved to treat psoriasis and PsA.

  • • Available formulations: 80-mg/mL solution in a single-dose prefilled autoinjector or syringe.
  • • Adult PsA dosage: 160-mg SC loading dose, then 80-mg SC every 4 weeks. Can be combined with a csDMARD (e.g., MTX).
  • • Adverse reactions, monitoring, and precautions similar to secukinumab.
15585

Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

15856
Scroll to Top